(Q37789741)

23 August 2017

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents (English)

1 reference

23 August 2017

0 references

Jihane Pakradouni

2

0 references

Jean-Pierre Rabès

Jean-Pierre Rabès

6

0 references

Mathilde Varret

Mathilde Varret

5

0 references

Catherine Boileau

Catherine Boileau

7

0 references

Marianne Abifadel

1

Marianne Abifadel

1 reference

PubMed ID

20849207

Marie-Elisabeth Samson-Bouma

23 August 2017

4

Marie-Elisabeth Samson-Bouma

1 reference

23 August 2017

Matthieu Collin

3

1 reference

PubMed ID

20849207

23 August 2017

language of work or name

English

0 references

publication date

17 September 2010

1 reference

Expert Opinion on Therapeutic Patents

23 August 2017

1 reference

23 August 2017

20

1 reference

23 August 2017

11

1 reference

23 August 2017

1547-1571

1 reference

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

23 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Familial hypercholesterolaemia in Portugal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Characterization of novel mutations in the catalytic domain of the PCSK9 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Biomedicine. Lowering LDL--not only how low, but how long?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Berberine decreases PCSK9 expression in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

LNA-mediated microRNA silencing in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

The utility of LNA in microRNA-based cancer diagnostics and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Molecular basis of PCSK9 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

Molecular basis for LDL receptor recognition by PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

PCSK9 as a therapeutic target of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2010.518615

10.1517/13543776.2010.518615

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20849207